April 24th 2024
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
April 23rd 2024
The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.
April 22nd 2024
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
April 19th 2024
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
April 18th 2024
Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
April 17th 2024
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.
B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.
April 15th 2024
The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.
April 11th 2024
The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
April 10th 2024
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
The Global Cancer Statistics, 2024, report from the American Cancer Society sheds light on worldwide cancer facts, identifying trends and making predictions for the future.
April 9th 2024
Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.
April 8th 2024
Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.
April 5th 2024
Afami-cel displayed activity in a heavily pretreated population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.
April 4th 2024
Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.
April 3rd 2024
Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.